Physician profile
Alvin Ginier
NPI 1619085800
$4,090.11
in general payments reported to CMS, 2019-2025
28 companies · $2,734 in 2025
The $2,734 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $38.03 · 2021: $152 · 2022: $260 · 2023: $246 · 2024: $661 · 2025: $2,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,310 · Food and Beverage: $1,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,309.79 |
| Food and Beverage | $1,330.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $2,309.79 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $298.40 | 2022-2025 | Farxiga, Lokelma, Tezspire |
| Paratek Pharmaceuticals, INC. | $231.73 | 2024-2025 | Nuzyra, Xhance |
| Biogen, INC. | $179.40 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Alcon Vision LLC | $152.54 | 2022-2025 | Clareon, Precision7 |
| Shield Therapeutics INC | $136.13 | 2024 | |
| Novo Nordisk INC | $107.29 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Vifor Pharma, INC. | $74.99 | 2021-2023 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.87 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $61.59 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.54 | 2020-2021 | |
| Abb Con-Cise Optical Group LLC | $53.66 | 2022 | |
| Cvrx, INC. | $44.27 | 2024 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $42.09 | 2023-2024 | Camzyos, Eliquis |
| Johnson & Johnson Vision Care, INC. | $31.06 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $27.29 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.09 | 2024 | Soliris |
| Travere Therapeutics, INC. | $22.15 | 2024 | |
| Abbvie INC. | $21.54 | 2022 | |
| Daiichi Sankyo INC. | $21.33 | 2022 | |
| Baxter Healthcare | $20.75 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2025 | Glassia |
| Argenx US, INC. | $19.17 | 2025 | Vyvgart |
| Organon LLC | $16.07 | 2023 | Ontruzant, Renflexis |
| Bausch & Lomb Americas INC. | $13.31 | 2022 | |
| Janssen Biotech, INC. | $13.09 | 2024 | Tremfya |
| Genentech USA, INC. | $12.72 | 2020 | |
| Lundbeck LLC | $11.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Ginier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.